Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer.

"J.K.C. reports research, consulting, and speaker’s bureau fees from AbbVie, Acerta, Aravive, AstraZeneca, Clovis, Eisai, GSK, Merck, and Roche. C.X., J.S., and E.W. are employees of Analysis Group, which received funding from GSK for the conduct of this study. P.H.T. reports institutional grants from GSK and Merck; and personal fees from AstraZeneca, Celsion, Clovis, GSK, Iovance, Novocure, and Seagen. L.K. and J.A.H. are employees of GSK. J.L. is a former employee of GSK."

"This study (OneCDP214309) was supported by GSK (Waltham, MA). Medical writing and editorial assistance, funded by GSK and coordinated by Hasan Jamal, MSc, of GSK, were provided by Shannon Morgan-Pelosi, PhD, and Jennifer Robertson, PhD, of Ashfield MedComms, an Inizio company."